- Aesthetic Treatment
- Therapeutic Treatment
Botox Treatment Market size is valued at USD 4,678.2 million in 2022 and is poised to grow at a CAGR of 11.9% from 2023 to 2029. The global market provides a detailed overview and which can be segmented by application, end user, and region. By application, the botox treatment market has been segmented into aesthetic treatment and therapeutic treatment. By application, the aesthetic treatment segment held the significant revenue share of the botox treatment market in 2021 and is expected to have the fastest growth rate over the forecasted period due to increasing aesthetic treatment across various age group people.Based on the end user, the segment has been segregated into hospitals, dermatology clinics, beauty clinics, spas, and salons. The dermatology clinics segment is expected to lead the end-user segments owing to rising awareness regarding various skin diseases, which undoubtedly increases the demand for botox treatment.
Botox Treatment Market Key Developments:
- In February 2020, Allergan plc declared its ‘Be the Difference’ philanthropic program supporting children and their families who may benefit from treatment with BOTOX (onabotulinumtoxinA) for pediatric upper limb spasticity. BOTOX is approved to treat increased muscle stiffness in children.
Botox Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
11%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Botox Treatment Market Dynamics
A rise in demand for aesthetics at present majorly affects the growth of the botox treatment industry. Also, the increase in launches of newer products for aesthetic appeal supporting minimally invasive procedures or even non-invasive procedures, which would support the industry to boost in the coming few years.
North-America Got Significant Share
Botox Treatment Market Regional Analysis
North American market is expected to witness the largest market share during the forecast period owing to the well-established healthcare facilities and rising patient population across the region, as well as increasing awareness about health.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Botox Treatment Market Segmentation
By Application
By End User
- Hospitals
- Dermatology Clinics
- Beauty Clinics
- Spas and Salons
By Geography
- Latin America
- North America
- Asia Pacific
- The Middle East and Africa
- Europe
Frequently Asked Questions
The global Botox Treatment market size is valued at USD 4,678.2 million in 2021 and is expected to grow at a significant CAGR of 11.9% during the forecast period 2022 to 2028.
Huge investment and increasing awareness for better health are the two key strategies opted for by the leading companies in the market.
Growth in the number of product launches will surely boost the market in the coming next few years.
Based on application, the aesthetic treatment during the forecast period, owing to rising aesthetic diseases across worldwide.
- Merz GmbH & Co. KGaA (Germany)
- ALLERGAN (Ireland)
- Ipsen (France)
- Galderma (Switzerland)
- Pfizer (US)
- Lumenis (U.S.)
- Canbex Therapeutics
- Takeda Pharmaceutical (Japan)
- Gal derma S/A (Switzerland)
- GlaxoSmithKline (UK)